L

Lunit Inc
KOSDAQ:328130

Watchlist Manager
Lunit Inc
KOSDAQ:328130
Watchlist
Price: 38 200 KRW 4.8% Market Closed
Market Cap: ₩1.4T

P/E

-16.4
Current
51%
Cheaper
vs 3-y average of -33.2

Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.

P/E
-16.4
=
Market Cap
₩1.1T
/
Net Income
₩-72.7B

Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.

P/E
-16.4
=
Market Cap
₩1.1T
/
Net Income
₩-72.7B

Valuation Scenarios

Lunit Inc is trading above its industry average

If P/E returns to its Industry Average (17.9), the stock would be worth ₩-41 755.51 (209% downside from current price).

Statistics
Positive Scenarios
0/2
Maximum Downside
-209%
Maximum Upside
No Upside Scenarios
Average Downside
197%
Scenario P/E Value Implied Price Upside/Downside
Current Multiple -16.4 ₩38 200
0%
Industry Average 17.9 ₩-41 755.51
-209%
Country Average 13.9 ₩-32 341.24
-185%

Forward P/E
Today’s price vs future net income

Not enough data available to calculate forward P/E

Peer Comparison

All Countries
Close

Market Distribution

Lower than 100% of companies in Korea
Percentile
0th
Based on 1 157 companies
0th percentile
-16.4
Low
0.2 — 8.5
Typical Range
8.5 — 23.4
High
23.4 —
Distribution Statistics
Korea
Min 0.2
30th Percentile 8.5
Median 13.9
70th Percentile 23.4
Max 7 223

Lunit Inc
Glance View

Market Cap
1.4T KRW
Industry
Health Care

Lunit Inc., founded in South Korea, stands as a pioneering force in the application of artificial intelligence within the realm of medical technology. As a company at the intersection of healthcare and cutting-edge AI, Lunit crafts advanced solutions that enhance the diagnostic processes in radiology and oncology. The company's name, derived from "learning unit," underscores its mission to employ deep learning as a core component in transforming medical diagnostics. At the heart of Lunit’s operations are their flagship products, Lunit INSIGHT and Lunit SCOPE, which are designed to empower physicians by providing highly accurate diagnostic readings and treatment predictions. With this technology, Lunit aims to reduce diagnostic errors and improve the efficiency of medical imaging analysis, ultimately enhancing patient treatment outcomes. Lunit generates revenue through strategic partnerships and sales of their AI software solutions to hospitals and healthcare providers globally. The company's business model involves not only licensing its AI technologies but also integrating them with existing medical imaging equipment, thus enhancing the value derived from traditional diagnostic tools. By collaborating with prominent medical device manufacturers and healthcare institutions, Lunit ensures both the scalability and adaptability of its products in diverse clinical settings. Additionally, they actively engage in research collaborations and pilot programs to further their technological advancements and expand their market presence. Through these endeavors, Lunit is steadily carving out a crucial role in the healthcare sector by offering AI-driven solutions that promise to revolutionize patient care.

Intrinsic Value
4 925.02 KRW
Overvaluation 87%
Intrinsic Value
Price ₩38 200
L
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett